BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.
LifeSci Advisors provides companies in the life sciences industry with comprehensive solutions to communications and investor outreach. LifeSci Advisors increases client visibility within the investment community and educates investors on opportunities offered by these companies. Our core capabilities include non-deal roadshow planning and execution, KOL Events/R&D Days and financial communications. With a local presence in New York, Chicago, Boston, London, Geneva, Paris, and Tel-Aviv, LifeSci Advisors provides high quality service for clients with our intensive healthcare sector specialization. The LifeSci team has 350+ years of healthcare experience in sell-side research, institutional equity sales, capital markets/investment banking, institutional investing, VC investing and strategic IR advisory. We have long-standing relationships with key investors and senior professionals across the industry. Our healthcare expertise allows us to provide objective, unbiased advice to private and public biotech, specialty pharma, medical technology, diagnostics, and healthcare services companies.
A global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
We are Merck, a vibrant science and technology company.
Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.
The passion of our curious minds makes a positive difference to millions of people’s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information.
Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live.
As the leading investment bank to the healthcare and life science industries, we help our clients move healthcare forward. With differentiated sector knowledge, unrivaled expertise, and a complete suite of capital market and advisory solutions, we are the industry's partner of choice. SVB Leerink is a wholly-owned subsidiary of SVB Financial Group and is a member of FINRA/SIPC.
INKEF Capital is an early stage venture capital firm based in Amsterdam. From the very early stages of a technology or lifescience venture, INKEF Capital supports entrepreneurs building their ideas into successful international businesses.
INKEF Capital covers multiple investment stages but focuses mainly on series A investments. For exceptional teams it also considers seed capital to turn a great idea into a company or growth capital to give a running start-up the next push. INKEF Capital is the partner for the long haul.
Latham & Watkins LLP is one of the largest law firms in the world with more than 3,000 lawyers located in major financial, business and regulatory centers around the globe. Our award-winning Healthcare & Life Sciences Industry guides clients through their most significant and cutting-edge legal challenges through a combination of in-depth industry knowledge, legal acumen, and strategic business advice. We understand the unique economic, market, regulatory and political climates in which healthcare and life sciences companies operate. www.lw.com
NOVO HOLDINGS A/S
Novo Ventures is a global team of investment professionals employed by Novo affiliates that supports Novo Holdings’ investments in private, public and structured product opportunities in the life sciences industry. Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Foundation’s assets. Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 29 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide. PharmaVentures' deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest. PharmaVentures’ services include:
M&A (divestments, mergers, acquisitions, and strategic transactions)
Licensing (in and out licensing)
Strategy (commercialisation, deal strategy, due diligence, market entry)
Valuation and Positioning (licensing, M&A, and fundraising)
PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific. PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).
The Swiss stock exchange is the leading European exchange operated by SIX that offers Swiss and international customers a comprehensive range of exchange services – listing, trading and post-trade solutions – from a single source. The Swiss stock exchange is the fourth biggest in Europe in both free-float market-cap and trading volume terms. It is one – of only 16 – trillion dollar exchanges worldwide. And it plays host to 2 of the 5 most capitalized companies in Europe as well as a broad universe of bonds, ETFs, Sponsored Funds, ETPs and Structured Products. When it comes to breaking new ground, we’re taking the industry lead. We already have fully functioning AI-based client interfaces for our post-trade operations and we’re well on our way to creating AI-data-analytics capabilities for more accurate macro-economic forecasting. Not to mention, of course, SIX Digital Exchange (SDX) – the world’s first regulated, end-to-end digital asset ecosystem.
Syneos Health™ is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial and consulting, work together to create customer success. Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum. We are uniquely positioned to bring into sharp focus the issues that matter most to biotech companies and investors through the breadth and depth of our network, and access to the expertise that the wider Syneos Health organization offers. At Syneos Health, clinical, commercial and consulting live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster. https://www.syneoshealth.com/